Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer-Reference-Cited by-同舟云学术

Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer

Published:2011-08-03 Issue:8 Volume:130 Page:1733-1744
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Sunaga Noriaki,Imai Hisao,Shimizu Kimihiro,Shames David S.,Kakegawa Seiichi,Girard Luc,Sato Mitsuo,Kaira Kyoichi,Ishizuka Tamotsu,Gazdar Adi F.,Minna John D.,Mori Masatomo

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference50 articles.

1. Targeting RAS signalling pathways in cancer therapy;Downward;Nat Rev Cancer,2003

2. A translational view of the molecular pathogenesis of lung cancer;Sato;J Thorac Oncol,2007

3. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features;Buttitta;Int J Cancer,2006

4. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis;Mascaux;Br J Cancer,2005

5. Current management of advanced non-small cell lung cancer: targeted therapy;Isobe;Semin Oncol,2005

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The concept of thromboinflammation underlying thrombotic complications, tumor progression and metastasis in gynecological cancer patients;Obstetrics, Gynecology and Reproduction;2024-09-12

2. MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer;Signal Transduction and Targeted Therapy;2024-08-21

3. In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors;OncoImmunology;2024-07-18

4. BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436;Breast Cancer Research and Treatment;2024-06-19

5. Unconventional strategy could be the future: From target to KRAS broad range treatment;Heliyon;2024-05